The company is focused on holistic medicine, nutritional supplements and “nutraceuticals” and aims to buy and scale around 15 brands over the next three years.
“The problem is every celebrity you can name is creating their own nutraceuticals and there is no credibility anymore for that, so there needs to be some kind of scientific validation,” Mr. Chopra told CNBC. “I decided I could help them with scientific validation of products and services.”
The company should also look into the use of psychedelics such as psilocybin and ketamine for treating mental health disorders, Mr. Chopra told CNBC.
Other investors include Dragons’ Den’s Steven Bartlett and psychedelics entrepreneur Christian Angermayer, who bought a stake in the company during a $10 million seed round.
